XML 42 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair value measurement (Tables)
 6 Months Ended
Jul. 01, 2018
Fair Value Disclosures [Abstract]  
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis
The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of July 1, 2018 and December 31, 2017:
 
Total carrying
value at
July 1, 2018
 
Quoted prices in active
markets (Level 1)
 
Significant other
observable
Inputs (Level 2)
 
Significant
unobservable
Inputs (Level 3)
 
(Dollars in thousands)
Investments in marketable securities
$
9,272

 
$
9,272

 
$
—

 
$
—

Derivative assets
1,954

 
—

 
1,954

 
—

Derivative liabilities
861

 
—

 
861

 
—

Contingent consideration liabilities
242,659

 
—

 
—

 
242,659

 
Total carrying
value at
December 31, 2017
 
Quoted prices in active
markets (Level 1)
 
Significant other
observable
Inputs (Level 2)
 
Significant
unobservable
Inputs (Level 3)
 
(Dollars in thousands)
Investments in marketable securities
$
9,045

 
$
9,045

 
$
—

 
$
—

Derivative assets
1,221

 
—

 
1,221

 
—

Derivative liabilities
1,426

 
—

 
1,426

 
—

Contingent consideration liabilities
272,136

 
—

 
—

 
272,136
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis
The following table provides information regarding changes, during the six months ended July 1, 2018, in Level 3 financial liabilities related to contingent consideration:
 
Contingent consideration
 
2018
 
(Dollars in thousands)
Balance - December 31, 2017
$
272,136

Additions (1)
396

Payment
(64,372
)
Revaluations
34,618

Translation adjustment
(119
)
Balance - July 1, 2018
$
242,659


(1) The Company established a liability related to the estimated fair value of contingent consideration associated with the acquired assets from QT Vascular.
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration recognized in connection with the NeoTract acquisition.
 
Valuation Technique
 
Unobservable Input
 
Range
Contingent consideration
Monte Carlo simulation
 
Revenue volatility
 
22.3
%
 
 
 
Risk free rate
 
Cost of debt structure

 

 
Projected year of payment
 
2018 - 2021